Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

Meet The Attys Guiding Genesis Healthcare' Ch. 11 No Photo Available

Yun Park

A team of lawyers from McDermott Will & Emery LLP is leading the bankruptcy case of Genesis Healthcare Inc., a holding company for reh... (more story)

Courts Face Early Push To Expand Justices' Injunction Ruling No Photo Available

Katie Buehler

In the two weeks since the U.S. Supreme Court curtailed federal judges' ability to issue universal injunctions, Trump administration a... (more story)

Retiring Fla. Judge Shares Fascination With Bankruptcy Law No Photo Available

Madison Arnold

Longtime Florida bankruptcy Judge Laurel M. Isicoff says that one of the great things about being a bankruptcy judge is the ability to... (more story)